文献速递临床试验与 GCP基础与转化研究

抢先治疗对比抗病毒预防对高危肝移植受者巨细胞病毒病的影响:一项随机临床试验

Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

该随机临床试验纳入205例CMV血清学阴性、供体阳性的肝移植受者,比较抢先治疗与抗病毒预防对12个月内CMV病发生率的影响。两组在移植物排斥、机会性感染、移植物丢失、中性粒细胞减少及死亡率方面无显著差异。

要点

  • 抢先治疗较抗病毒预防显著降低高危肝移植受者12个月CMV病发生率(9% vs 19%)。
  • 两组急性排斥、机会性感染、移植物丢失及中性粒细胞减少发生率无显著差异。
  • 抢先治疗策略需每周监测血浆CMV PCR,直至连续两次阴性。

核心结论

  • 在CMV血清学阴性、供体阳性的肝移植受者中,抢先治疗相比抗病毒预防可降低12个月内CMV病发生率。

研究设计与样本

  • 随机临床试验,纳入205例CMV血清学阴性、供体阳性的肝移植受者,年龄大于18岁,在美国6个学术移植中心开展。
  • 患者按1:1随机分配至抢先治疗组(n=100)或抗病毒预防组(n=105),所有患者完成试验。

主要发现

  • 移植物排斥发生率抢先治疗组28% vs 预防组25%,差异3%(95%CI -9%至15%)。
  • 机会性感染发生率抢先治疗组25% vs 预防组27%,差异2%(95%CI -14%至10%)。
  • 移植物丢失发生率两组均为2%,差异小于1%(95%CI -4%至4%)。
  • 中性粒细胞减少发生率抢先治疗组13% vs 预防组10%,差异3%(95%CI -5%至12%)。

关键数值与推荐

  • 抢先治疗:每周血浆CMV PCR监测100天,对检测到的病毒血症给予缬更昔洛韦900 mg每日两次,直至连续两次间隔一周的检测阴性。
  • 抗病毒预防:缬更昔洛韦900 mg每日一次,持续100天。
  • 主要结局为12个月内CMV病发生率,定义为CMV综合征或终末器官疾病。

临床怎么用

  • 对于CMV血清学阴性、供体阳性的肝移植受者,可考虑采用抢先治疗策略以降低CMV病风险。
  • 抢先治疗需建立可靠的每周CMV PCR监测体系。

局限性

  • 研究仅纳入6个美国学术移植中心,结果外推需谨慎。
  • 作者指出需进一步研究重复这些发现并评估长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Despite the use of a cytomegalovirus (CMV) prevention strategy of antiviral prophylaxis for high-risk CMV-seronegative liver transplant recipients with seropositive donors, high rates of delayed-onset postprophylaxis CMV disease occur. An alternate approach, preemptive therapy (initiation of antiviral therapy for early asymptomatic CMV viremia detected by surveillance testing), has not previously been directly compared with antiviral prophylaxis in these patients. OBJECTIVE: To compare preemptive therapy with antiviral prophylaxis in CMV-seronegative liver transplant recipients with seropositive donors for the prevention of CMV disease. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial of preemptive therapy vs antiviral prophylaxis in 205 CMV-seronegative liver transplant recipients with seropositive donors aged older than 18 years. The trial was conducted at 6 academic transplant centers in the United States between October 2012 and June 2017, with last follow-up in June 2018. INTERVENTIONS: Patients were randomized 1:1 to receive either preemptive therapy (valganciclovir, 900 mg, twice daily until 2 consecutive negative tests a week apart) for viremia detected by weekly plasma CMV polymerase chain reaction for 100 days (n = 100) or valganciclovir, 900 mg, daily for 100 days as antiviral prophylaxis (n = 105). MAIN OUTCOMES AND MEASURES: The primary outcome was incidence of CMV disease by 12 months, defined as CMV syndrome (CMV viremia and clinical or laboratory findings) or end-organ disease. Secondary outcomes included acute allograft rejection, opportunistic infections, graft and patient survival, and neutropenia. RESULTS: Among 205 patients who were randomized (mean age, 55 years; 62 women [30%]), all 205 (100%) completed the trial. The incidence of CMV disease was significantly lower with preemptive therapy than antiviral prophylaxis (9% [9/100] vs 19% [20/105]; difference, 10% [95% CI, 0.5% to 19.6%]; P = .04]). The incidence of allograft rejection (28% vs 25%; difference, 3% [95% CI, -9% to 15%]), opportunistic infections (25% vs 27%; difference, 2% [95% CI, -14% to 10%]), graft loss (2% vs 2%; difference, <1% [95% CI, -4% to 4%]), and neutropenia (13% vs 10%; difference, 3% [95% CI, -5% to 12%]) did not differ significantly for the preemptive therapy vs antiviral prophylaxis group, respectively. All-cause mortality at last follow-up was 15% in the preemptive therapy vs 19% in the antiviral prophylaxis group (difference, 4% [95% CI, -14% to 6%]; P = .46). CONCLUSIONS AND RELEVANCE: Among CMV-seronegative liver transplant recipients with seropositive donors, the use of preemptive therapy, compared with antiviral prophylaxis, resulted in a lower incidence of CMV disease over 12 months. Further research is needed to replicate these findings and assess long-term outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01552369.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Singh N, Winston DJ, Razonable RR, et al. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial. JAMA. 2020. PMID: 32286644. doi:10.1001/jama.2020.3138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。